Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 4, 2007, Pages 867-872

  Fukushiro, Daniela Fukue ^a   Alvarez, Juliana do Nascimento ^a   Tatsu, Julie Anne Obara ^a   de Castro, Juliana Pedroso Moraes Vilela ^a   Chinen, Cibele Cristina ^a   Frussa Filho, Roberto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cocaine; Conditioned place preference; Haloperidol; Hyperactivity; Ziprasidone

Indexed keywords

COCAINE; HALOPERIDOL; ZIPRASIDONE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG WITHDRAWAL; EXPERIMENTAL MOUSE; LOCOMOTION; LONG TERM CARE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PLACE PREFERENCE; TREATMENT WITHDRAWAL;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; COCAINE; CONDITIONING, OPERANT; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; HALOPERIDOL; MALE; MICE; MOTOR ACTIVITY; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 34247474819     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.01.025     Document Type: Article

References (43)

1. Abílio V.C., Freitas F.M., Dolnikoff M.S., Castrucci A.M., and Frussa-Filho R. Effects of continuous exposure to light on behavioral dopaminergic supersensitivity. Biol Psychiatry 42 12 (1999) 1622-1629
2. Abílio V.C., Vera Jr. J.A., Ferreira L.S., Duarte C.R., Martins C.R., Torres-Leite D., et al. Effects of melatonin on behavioral dopaminergic supersensitivity. Life Sci 72 26 (2003) 3003-3015
3. Adams J.U., Careri J.M., Efferen T.R., and Rotrosen J. Differential effects of dopamine antagonists on locomotor activity and conditioned place preference induced by cocaine in rats. Behav Pharmacol 12 8 (2001) 603-611
4. Carey R., Damianopoulos E., and De Palma G. 8-OHDPAT can restore the locomotor stimulant effects of cocaine blocked by haloperidol. Pharmacol Biochem Behav 66 4 (2000) 863-872
5. 2-like dopamine receptors in the locomotor stimulant effects of cocaine in mice. Psychopharamcology (Berl) 155 1 (2001) 69-77
6. Chinen C.C., Faria R.R., and Frussa-Filho R. Characterization of the rapid-onset type of behavioral sensitization to amphetamine in mice: role of drug-environment conditioning. Neuropsychopharmacology 31 1 (2006) 151-159
7. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85 14 (1988) 5274-5278
8. Fenton W.s., Blyler C.r., and Heinssen R.k. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23 4 (1997) 637-651
9. Frussa-Filho R., and Palermo-Neto J. Effects of single and long-term metoclopramide administration on open-field and stereotyped behavior of rats. Eur J Pharmacol 149 3 (1988) 323-329
10. Frussa-Filho R., and Palermo-Neto J. Effects of single and long-term administration of sulpiride on open-field and stereotyped behavior of rats. Braz J Med Biol Res 23 5 (1990) 463-472
11. Frussa-Filho R., and Palermo-Neto J. Effects of single and long-term droperidol administration on open-field and stereotyped behavior of rats. Physiol Behav 50 4 (1991) 825-830
12. Hartfield A.W., Moore N.A., and Clifton P.G. Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats. Neuropsychopharmacology 31 9 (2006) 1938-1945
13. 1 dopamine receptor sensitivity within the rat nucleus accumbens. J Pharmacol Exp Ther 258 (1991) 882-890
14. Kelly P.H., Seviour P.W., and Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 94 (1975) 507-522
15. Koob G.F., and LeMoal M. Neurobiological theories of addiction. In: Koob G.F., and LeMoal M. (Eds). Neurobiology of addiction (2006), Academic Press, London 377-428
16. Kosten T.A., DeCaprio J.L., and Nestler E.J. Long-term haloperidol administration enhances and short-term administration attenuates the behavioral effects of cocaine in a place conditioning procedure. Psychopharmacology 128 (1996) 304-312
17. LeDuc P.A., and Mittleman G. Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations. Psychopharmacology (Berl) 110 4 (1993) 427-436
18. LeDuc P.A., and Mittleman G. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence (review). Psychopharmacology (Berl) 121 4 (1995) 407-427
19. Martin J.L., and Itzhak Y. 7-Nitroindazole blocks nicotine-induced conditioned place preference but not LiCl-induced conditioned place aversion. NeuroReport 11 5 (2000) 947-949
20. Meyer J.S., and Quenzer L.F. Schizophrenia. In: Meyer J.S., and Quenzer L.F. (Eds). Psychopharmacology: drugs, the brain and behavior (2005), Sinaver Associates Inc., Sunderland 441-467
21. Muller P., and Seeman P. Dopaminergic supersensitivity after neuroleptics: time-course and specificity. Psychopharmacology (Berl) 60 1 (1978) 1-11 [Review]
22. Palermo-Neto J., and Frussa-Filho R. Behavioral models of tardive dyskinesia in rodents. A chronological overview. In: Bolis C.L., Pani L., and Licinio J. (Eds). Dopaminergic system: evolution from biology to clinical aspects. USA (2001) 61-82
23. Pijnenburg A.J., Honig W.M., and Van Rossum J.M. Inhibition of d-amphetamine-induced locomotor activity by injection of haloperidol into the nucleus accumbens of the rat. Psychopharmacologia 41 (1975) 87-95
24. Potvin S., Stip E., and Roy J.Y. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses (review). Int Clin Psychopharmacol 18 3 (2003) 121-132
25. Prosser E.S., Csernansky J.G., and Hollister L.E. Differences in the time course of haloperidol-induced up-regulation of rat striatal and mesolimbic dopamine receptors. Life Sci 43 8 (1988) 715-720
26. Prosser E.S., Pruthi R., and Csernansky J.G. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. Psychopharmacology (Berl) 99 1 (1989) 109-116
27. Queiroz C.M., and Frussa-Filho R. Effects of buspirone on dopaminergic supersensitivity. Life Sci 61 4 (1997) 371-382
28. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 264 19 (1990) 2511-2518
29. Robinson T.E., and Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction (review). Brain Res Rev 18 3 (1993) 247-291
30. Romieu P., Phan V.L., Martin-Fardon R., and Maurice T. Involvement of the Sigma (1) receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 26 4 (2002) 444-455
31. Rupniak N.M., Hall M.D., Mann S., Fleminger S., Kilpatrick G., Jenner P., et al. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem Pharmacol 34 15 (1985) 2755-2763
32. 2 antagonists modulate the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 253 3 (1990) 1162-1170
33. Schmidt A.W., Lebel L.A., Howard Jr. H.R., and Zorn S.H. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425 3 (2001) 197-201
34. Self D.W., and Nestler E.J. Molecular mechanisms of drug reinforcement and addiction (review). Ann Rev Neurosci 18 (1995) 463-495
35. Shippenberg T.S., and Koob G.F. Recent advances in animal models of drug addiction. In: Davis K.L., Charney D., Coyle J.T., and Nemeroff C. (Eds). Neuropsychopharmacology: the fifth generation of progress (2002), Lippincott Williams and Wilkins, Philadelphia 1381-1397
36. 4-like dopamine receptors. Neuropsychopharmacology 17 3 (1997) 186-196
37. Tsuang J.W., Eckman T., Marder S., and Tucker D. Can risperidone reduce cocaine use in substance abusing schizophrenic patients?. J Clin Psychopharmacol 22 6 (2002) 629-630
38. Tsuang J.W., Marder S.R., Han A., and Hsieh W. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry 63 12 (2002) 1180-1181
39. Vital M.A., Frussa-Filho R., and Palermo-Neto J. Effects of monosialoganglioside on dopaminergic supersensitivity. Life Sci 56 26 (1995) 2299-2307
40. Waddington J.L. New antipsychotic drugs: preclinical evaluation and clinical profiles in the treatment of schizophrenia. In: Reveley M.A., and Deakin J.F.W. (Eds). The psychopharmacology of schizophrenia (2000), Arnold, London
41. Wise R.A. The neurobiology of craving: implications for the understanding and treatment of addiction (review). J Abnorm Psychol 97 2 (1988) 118-132
42. Wolf M.E., White F.J., and Hu X.T. MK-801 prevents alterations in the mesoaccumbens dopamine system associated with behavioral sensitization to amphetamine. J Neurosci 14 Part 2 (1994) 1735-1745
43. Young J.l., Zonana H.v., and Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psych Law 14 (1986) 105-122